10 of the Most Controversial Deals in Medtech

Some companies were able to overcome the odds despite controversy and close on the acquisitions. Others weren’t as fortunate, and the mergers folded. MD+DI has compiled a list of some of the most controversial deals the medtech industry has ever seen.

Earlier this week, it was announced the Delaware Court of Chancery ruled that Hillrom must proceed with its $375 million acquisition of Bardy Diagnostics. Chicago, IL-based Hillrom wanted to back out of the deal because it claimed Medicare rate cuts for long-term cardiac monitoring constituted a material adverse event in the acquisition agreement. Hillrom said it plans to appeal the decision. It still remains to be seen if the deal will go through.

It’s not the first time a medtech deal has been in jeopardy. MD+DI has compiled a list of 10 mergers and acquisitions that have faced controversy and, in some cases, insurmountable odds. We should note, not all of the deals closed and some came to a screeching halt.